Financial Report: Lilly

Lilly
 
3Q Revenues: $5.2 billion (+5%)

3Q Earnings:  $778.0 million (-3%)

YTD Revenues: $15.5 billion (+6%)

YTD Earnings: $2.0 billion (+2%)

Comments: Newer pharmaceutical products boosted sales in the quarter. Trulicity sales were $243.6 million in the quarter. Cyramza sales were up 43% to $159.0 million. Taltz sales were $32.5 million and Jardiance sales were $47.5 million in the quarter. Humalog sales were down 9% to $640.8 million driven by lower realized prices, partially offset by increased demand. Forteo sales were $391.2 million, up 12%. Humulin revenues increased 2% to $322.0 million in the quarter. Erbitux sales were $184.6 million, up 115%, partially offset by lower volumes for Zyprexa, down 37% to $149.8 million. Animal health sales were $706.2 million, down 9%. Alimta sales were $570.4 million, down 9%. Cialis sales were $588.2 million, up 4%. The company recognized asset impairment, restructuring and other special charges of $45.5 million and $42.4 million in the third quarters of 2016 and 2015, respectively, primarily related to integration and severance costs for Novartis Animal Health.